The evolution of drug research and development toward oral therapies for cancer over the past decade has created a number of questions for the oncology healthcare provider. Will insurance companies pay for these exceptionally expensive medications? How and when will patients receive their medication? Who will be responsible for ensuring patient education and monitoring to maximize safe drug administration and patient compliance?
Monroe Township, NJ and Boston, MA, January 24, 2012 — A formal alliance known as The Lynx Group™ has been established between 4 privately owned medical communication companies each with a unique niche and expertise in the healthcare industry: Engage Healthcare Communications, Green Hill Healthcare Communications, Core Principle Solutions, and Center of Excellence Media.
Dr Hansen provided a comprehensive review of the challenges patients face when diagnosed with cancer. She illustrated that while improved survival is a welcome benefit to many of today’s cancer patients, psychological, social, and emotional struggles exist. Several considerations come to mind, such as where does one obtain information regarding care? Does the patient- provider relationship affect treatment, and what is the role of the oncology nurse (ON) in the care of cancer patients?
The article by Dr Hansen provides a great overview of the challenges facing patients from initial diagnosis of cancer through survivorship. Patients typically are diagnosed with cancer suddenly in the midst of living their lives. The various stressors in life that exist prior to diagnosis can be further exacerbated after diagnosis. As oncology providers, in addition to having knowledge of the options to treat a patient’s cancer, we need to make sure we understand the patient as a whole— both the patient and the person.
The diagnosis of cancer is arguably one of the most emotionally exhausting and potentially psychologically debilitating medical conditions we may experience during our lifetime. However, the impact of this diagnosis is not limited to the patient and frequently resonates among family members, friends, and caregivers as well. When the impact of cancer on the human condition is combined with the knowledge that healthcare practitioners are frequently unable to detect psychological distress in this patient population, the effects can be profound.1
ADCETRIS™ (brentuximab vedotin), a new CD30-directed antibody-drug conjugate (ADC), was approved by the U.S. Food and Drug Administration (FDA) on August 19, 2011, for the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens. ADCETRIS is also indicated for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least 1 prior multiagent chemotherapy regimen.1
CHICAGO—Women considered at risk for breast cancer developed fewer breast cancers and fewer precursor lesions by taking the aromatase inhibitor (AI) exemestane for 5 years, versus placebo, in a large Canadian study presented at the 2011 annual meeting of the American Society of Clinical Oncology.
CHICAGO—More support for bevacizumab in the treatment of ovarian cancer emerged at the 2011 annual meeting of the American Society of Clinical Oncology, with studies showing the drug prolongs the time to disease progression, both in the metastatic and primary disease settings.
Results 41 - 50 of 78